申请人:Bristol-Myers Squibb Company
公开号:US05321036A1
公开(公告)日:1994-06-14
Compounds having the formula ##STR1## and pharmaceutically acceptable salts thereof where A is ##STR2## R.sub.3 is --(CH.sub.2).sub.n -- or in the case where R.sub.2 is ##STR3## R.sub.3 in addition to the above may be ##STR4## R.sub.4 is hydroxy, alkoxy, amino, alkylamino or dialkylamino; R.sub.5 is hydrogen, fluorine, chlorine, bromine, iodine, --CN, CF.sub.3, lower alkyl, lower alkoxy, cycloalkyl or aryl; R.sub.6 is lower alkyl, cycloalkyl or aryl; R.sub.7, R.sub.7 ', R.sub.8 and R.sub.8 ' are independently hydrogen or a lower alkyl or R.sub.7 and R.sub.8 may together be CH.sub.2 CH.sub.2 ; Z is hydrogen or ##STR5## m is an integer of 1 or 2; n is zero or an integer of 1 to 6; and p is an integer of 1 to 5. These compounds are beta 3 adrenergic receptor agonists and are useful, therefore for example, in the treatment of diabetes, obesity and gastrointestinal diseases.
具有如下结构式##STR1##及其药用盐的化合物,其中A为##STR2##,R.sub.3为--(CH.sub.2).sub.n--或者在R.sub.2为##STR3##的情况下,R.sub.3还可以是##STR4##,R.sub.4为羟基、烷氧基、氨基、烷基氨基或二烷基氨基;R.sub.5为氢、氟、氯、溴、碘、--CN、CF.sub.3、低烷基、低烷氧基、环烷基或芳基;R.sub.6为低烷基、环烷基或芳基;R.sub.7、R.sub.7'、R.sub.8和R.sub.8'独立地为氢或低烷基,或者R.sub.7和R.sub.8可以一起为CH.sub.2CH.sub.2;Z为氢或##STR5##,m为1或2的整数;n为0或1至6的整数;p为1至5的整数。这些化合物是β3肾上腺素受体激动剂,因此在糖尿病、肥胖和胃肠疾病的治疗中是有用的。